Average weight loss on Mounjaro 2.5mg: what actually happens in the first four weeks

You've just started 2.5mg and the scales haven't moved much

This is the scenario most people find themselves in after the first few weeks, and the most common question our prescribers hear. You read about 20% weight loss in the trial results, and your first pen hasn't delivered anything close to that. It hasn't failed, it hasn't really started yet.

The 2.5mg dose was designed specifically as an introductory step. Tirzepatide activates both GLP-1 and GIP receptors, which influence appetite signalling and slow how quickly the stomach empties. Those effects build with the dose. At 2.5mg, the appetite suppression is real but relatively mild, and the body is still adapting to the medicine. Think of it like the first week of a new exercise routine: the work is happening, but the results lag behind.

The NHS patient information for tirzepatide confirms that treatment starts at 2.5mg and is titrated upward by the prescriber, typically every four weeks, toward the dose that suits you. The trial results people read about (and the figures cited in NICE's appraisal of tirzepatide (TA1026)) were measured at the end of 72 weeks, not at the end of week four at the lowest dose.

If you are curious about what comes next, the comparison between 2.5mg and 5mg in terms of weight loss explains what changes as the dose steps up.

What the SURMOUNT-1 trial actually measured, and where 2.5mg sits in it

SURMOUNT-1 is the pivotal phase-3 trial for tirzepatide in weight management. It randomised 2,539 adults with obesity and no diabetes, tracked them for 72 weeks, and tested three maintenance doses: 5mg, 10mg and 15mg. Everyone started at 2.5mg. That starting phase was a run-in designed to reduce early side effects, not a treatment condition in its own right.

The headline results (average body-weight reductions of around 15% at 5mg, 19.5% at 10mg, and roughly 20–21% at 15mg) were measured at the end of the full 72-week period, across participants who reached and stayed on those maintenance doses. The SURMOUNT-1 paper in the New England Journal of Medicine describes this progression in detail. There is no published figure for weight loss at 2.5mg in isolation, because that was never the end-point being measured.

What this means practically: the first pen is adjusting your system. If you want to understand what to expect from Mounjaro at the 2.5mg stage, including why results are modest at this point, it helps to look at this dose on its own terms before comparing it to the full trial outcomes. Patience at this stage is not a passive choice; it is part of the treatment design.

For a fuller picture of what higher doses tend to produce, the detail on weight loss at 7.5mg shows where most people's results start to become more visible.

Side effects at the starter dose, what's common, what to watch for

The most frequently reported side effects of Mounjaro are gastrointestinal: nausea, constipation, loose stools, reflux and burping. These tend to be at their most noticeable when treatment begins or after each dose step. At 2.5mg, the lower level of receptor activation generally means side effects are milder than they will be at the maintenance dose, which is one reason the schedule starts here.

For most people they ease within ten to fourteen days. Eating smaller portions, avoiding very fatty or rich meals, and staying well hydrated all help. The NHS guidance on tirzepatide covers these in more detail and is worth reading alongside the patient information leaflet that comes with your pen.

One side effect that is less common but important: severe, persistent stomach pain that radiates to the back (with or without vomiting) can be a sign of pancreatitis, a serious but infrequent complication. The MHRA highlighted this in a Drug Safety Update for GLP-1 medicines and advises seeking urgent medical help if it occurs. Do not wait for your next scheduled check-in.

If side effects at 2.5mg are troubling you, speak to your prescriber before deciding to stop. Slowing a planned dose increase, or pausing before the next step, is sometimes the right clinical call. That is not a failure of the medicine; it is the titration working as intended. You can reach our support team seven days a week if you have questions between reviews.

What happens after 2.5mg, and how that affects your results

After roughly four weeks at 2.5mg, your prescriber will review your response. If you have tolerated the dose well (side effects manageable, no red flags) the next step is typically 5mg, and reading about what Mounjaro at 5mg tends to deliver in terms of weight loss can help you set realistic expectations before you make that move. From there, the titration continues in four-week steps through 7.5mg, 10mg, 12.5mg and up to 15mg, depending on how your body responds and what the prescriber considers appropriate. You do not have to reach the highest dose to get a meaningful result; many people find a good balance at a mid-range strength.

The cost of private treatment varies by dose and by how long you continue, which our treatment overview explains clearly alongside eligibility information. It is worth understanding the full picture before you begin, rather than making decisions pen by pen.

The 10mg dose page covers what the trial data shows at that strength, if you want to plan ahead. And if you have not yet started treatment, the Mounjaro overview explains the licence, the mechanism and what UK private access looks like in full.

One practical note: if you order before midday on a working day and your consultation is approved, your medication is dispatched the same afternoon and arrives the next working day via DPD, tracked, in plain packaging, so there is nothing to give it away when it lands on the doormat. That reliability matters when you are trying to stay on a four-week schedule.

Ready to check whether you meet the eligibility criteria? Check your eligibility with our prescribers, the consultation is free, and a real clinician reviews every application the same day.